<DOC>
	<DOC>NCT02449018</DOC>
	<brief_summary>To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)</brief_summary>
	<brief_title>A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Must have a diagnosis of GOLD IIIII chronic obstructive pulmonary disease (COPD); Must have clinical diagnosis of chronic bronchitis; Must be either a current smoker (smoked â‰¤ 1 pack per day on average for the last 3 months with at least a 10 pack year smoking history) OR an exsmoker with at least a 10 pack year smoking history; Must not be receiving chronic, daily, systemic steroids; Must not have severe emphysema (determined by HRCT); Must not have had a COPD exacerbation or respiratory tract infection requiring antibiotics or oral steroids or hospitalization within 6 weeks of screening; Must not be pregnant or nursing or a woman of child bearing potential; Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD,</keyword>
	<keyword>chronic bronchitis,</keyword>
	<keyword>inflammation,</keyword>
	<keyword>airway,</keyword>
	<keyword>LCI,</keyword>
	<keyword>pulmonary function test,</keyword>
	<keyword>lung function,</keyword>
	<keyword>controlled clinical trial,</keyword>
	<keyword>randomized,</keyword>
	<keyword>airflow,</keyword>
	<keyword>smoker</keyword>
</DOC>